These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3104262)

  • 41. In vitro characterization and in vivo testosterone suppression of 6-month release poly(D,L-lactide) leuprolide microspheres.
    Woo BH; Na KH; Dani BA; Jiang G; Thanoo BC; DeLuca PP
    Pharm Res; 2002 Apr; 19(4):546-50. PubMed ID: 12033393
    [No Abstract]   [Full Text] [Related]  

  • 42. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement.
    Okada H; Yamazaki I; Ogawa Y; Hirai S; Yashiki T; Mima H
    J Pharm Sci; 1982 Dec; 71(12):1367-71. PubMed ID: 6818337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer.
    Ogawa Y; Yamamoto M; Takada S; Okada H; Shimamoto T
    Chem Pharm Bull (Tokyo); 1988 Apr; 36(4):1502-7. PubMed ID: 3138032
    [No Abstract]   [Full Text] [Related]  

  • 44. Controlled release of therapeutic agents: slow delivery and cell encapsulation.
    Machluf M; Orsola A; Atala A
    World J Urol; 2000 Feb; 18(1):80-3. PubMed ID: 10766049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Experience in the use of nafarelin for treatment of benign breast disease.
    Roberts JV
    Br J Clin Pract Suppl; 1989 Nov; 68():37-42; discussion 49-53. PubMed ID: 2535115
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacokinetics of gonadotropin-releasing hormone and its analogs.
    Handelsman DJ; Swerdloff RS
    Endocr Rev; 1986 Feb; 7(1):95-105. PubMed ID: 3007081
    [No Abstract]   [Full Text] [Related]  

  • 47. Bioavailability of nafarelin in healthy volunteers.
    Chaplin MD
    Am J Obstet Gynecol; 1992 Feb; 166(2):762-5. PubMed ID: 1531580
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers.
    Adjei A; Garren J
    Pharm Res; 1990 Jun; 7(6):565-9. PubMed ID: 2114618
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nasal absorption of propranolol from different dosage forms by rats and dogs.
    Hussain A; Hirai S; Bawarshi R
    J Pharm Sci; 1980 Dec; 69(12):1411-3. PubMed ID: 7463327
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats II: mechanism of absorption enhancement with organic acids.
    Okada H; Yamazaki I; Yashiki T; Mima H
    J Pharm Sci; 1983 Jan; 72(1):75-8. PubMed ID: 6402584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LHRH analogues in the treatment of cancer.
    Jackson IM; Matthews MJ; Diver JM
    Cancer Treat Rev; 1989 Sep; 16(3):161-75. PubMed ID: 2695240
    [No Abstract]   [Full Text] [Related]  

  • 52. Applications of LhRh agonists against a wide range of gynecologic cancers.
    Bruckner HW; Motwani BT
    J Clin Oncol; 1989 Jun; 7(6):816-7. PubMed ID: 2497230
    [No Abstract]   [Full Text] [Related]  

  • 53. [Effect of the intraventricular administration of gonadotropin-releasing hormone analogue on immune response and unspecific resistance in rats].
    Bobyntsev II; Sever'ianova LA; Smakhtin MIu; Ktiukov AA
    Ross Fiziol Zh Im I M Sechenova; 2005 Oct; 91(10):1176-81. PubMed ID: 16335425
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Silica-based size exclusion chromatography to characterize the decapeptide nafarelin in a controlled-release pharmaceutical formulation.
    Kenley RA; Hamme KJ; Lee MO; Tom J
    Anal Chem; 1987 Sep; 59(17):2050-4. PubMed ID: 2960251
    [No Abstract]   [Full Text] [Related]  

  • 55. Letter: Intranasal administration of luteinising-hormone releasing factor.
    Gennser G; Liedholm P
    Lancet; 1974 May; 1(7862):865. PubMed ID: 4132813
    [No Abstract]   [Full Text] [Related]  

  • 56. Hypersensitivity reaction to intranasal gonadotropin-releasing hormone.
    Mayr J; Aigner R
    Eur J Pediatr; 1995 Mar; 154(3):248. PubMed ID: 7758533
    [No Abstract]   [Full Text] [Related]  

  • 57. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.
    Kamaly N; Yameen B; Wu J; Farokhzad OC
    Chem Rev; 2016 Feb; 116(4):2602-63. PubMed ID: 26854975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical pharmacokinetics of depot leuprorelin.
    Periti P; Mazzei T; Mini E
    Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
    Plosker GL; Brogden RN
    Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gonadotrophin-releasing hormone agonists. A guide to use and selection.
    Filicori M
    Drugs; 1994 Jul; 48(1):41-58. PubMed ID: 7525194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.